Updated Glossary of Common Ingredient Names
The European Commission has published the Commission Implementing Decision (EU) 2022/677, which updates the Glossary of common ingredient names for use in the labelling of cosmetic products.
Picture of Marta Pinto

Marta Pinto

Regulatory Affairs Associate
Linkedin Instagram Facebook Address-card

GLOSSARY OF COMMON INGREDIENT NAMES

Article 19 of Regulation (EC) No 1223/2009 on cosmetic products lays down the mandatory information that needs to be included in the packaging and container of cosmetic products. (see previous publication) One of the requirements is the inclusion of a list of ingredients, in descending order of concentration.

According to the Cosmetics Regulation, an “ingredient means any substance or mixture intentionally used in the cosmetic product during the process of manufacturing“. Impurities in the raw materials used and subsidiary technical materials used in the mixture (but not present in the final product) are not considered ingredients.

Article 33 to Regulation states that the European Commission shall compile and update a glossary of common ingredient names, taking into account internationally recognized nomenclatures, including the International Nomenclature of Cosmetic Ingredients (INCI). The glossary does not constitute a list of the substances authorized for use in cosmetic products.

The terms ‘parfum’ or ‘aroma’ shall be used to identify perfume and aromatic compositions and their raw materials. Some ingredients used in perfume and aromatic compositions do not have an INCI name. In these cases, ‘perfuming names’ are used which have been used in the EU for labelling cosmetics containing those ingredients. Moreover, for colorants (other than colorants intended to color the hair), the CI (Colour Index) nomenclature is to be used. As so, perfuming names and CI nomenclature are included in the glossary of ingredients.

For the purpose of labelling cosmetics, the ingredients are to be expressed using the common ingredient name set out in glossary compiled and updated by the European Commission.

COMMISION IMPLEMENTING DECISION (EU) 2022/677

Taking into account the new ingredient names that are currently in use for cosmetic products marketed in the EU, the Decision (EU) 2019/71, which set out the glossary of common ingredient names (26 491 ingredients in total) , is replaced.

The European Commission has published the Commission Implementing Decision (EU) 2022/677, laying down the rules for the application of Regulation No 1223/2009 as regards the glossary of common ingredient names for use in the labelling of cosmetic products.

The updated on the glossary has included new INCI names as published by the Personal Care Products Council and has corrected existing ingredient names that were erroneously reported or omitted. The updated glossary lists 30 070 ingredients.

The Commission Implementing Decision (EU) 2022/677 applies from 29 April 2023. From 29 April 2022 until 28 April 2023, the economic operators may use the common ingredient names set out in the Annex of this Implementing Decision, for the purpose of compliance with labelling requirements.

Not sure if your cosmetic product labelling is compliant with regulation? Critical Catalyst can help! Feel free to contact us at info@criticalcatalyst.com.

References:

  1. Regulation (EC) No 1223/2009 of the European Parliament and of the Council of 30 November 2009 on cosmetic products.
  2. Commission Decision (EU) 2019/701 establishing a glossary of common ingredient names for use in the labelling of cosmetic products. 2019.
  3. Commission Implementing Decision (EU) 2022/677 laying down rules for the application of Regulation (EC) No 1223/2009 of the European Parliament and of the Council as regards the glossary of common ingredient names for use in the labelling of cosmetic products. 2022.

further
reading
medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
Guilherme Semedo February 24, 2023
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
Guilherme Semedo February 15, 2023
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
Guilherme Semedo February 13, 2023
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
Guilherme Semedo January 9, 2023
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
Guilherme Semedo December 13, 2022
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
Liliana Teles December 10, 2022
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
Filipa Ferreira October 11, 2022
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »
Filipa Ferreira October 4, 2022

services

CONTACT US

  • info@criticalcatalyst.com
  • +351 91 200 43 51
    PT mobile network call
  • EUROPEAN UNION (HQ)
    679 Avenida da República
    4450-242 Matosinhos (PT)
  • UNITED KINGDOM
    49 Queen Victoria Street
    EC4N 4SA London (UK)